Jump to content
CME Institute login
Bookmark/Search this post
You are here
Tweetorial: A Rationale for Treating CKD with Combination Therapy
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.
An Individualized Approach to PAH Therapy Based on Clinical Data, Goal-Directed Therapy, and Risk Stratification
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
Translating Clinical Trial Data into Real-World Practice: Examining CKD Screening and Three Patient Case Profiles
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.
Improving Standards of Care in Type 2 Diabetes with Chronic Kidney Disease: Integrating the Non-Steroidal Mineralocorticoid Antagonist Class in Cardiorenal Medicine
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression